BAAM
BIO icon

Baker Avenue Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Baker Avenue Asset Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-20
Closed -$7.17K – 497
2023
Q3 		$7.17K Buy
20
+16
+400% +$6.17K ﹤0.01% 847
2023
Q2 		$1.52K Buy
+4
New +$1.63K ﹤0.01% 1047

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Baker Avenue Asset Management's BIO Position: Q4 2023 in Review

Baker Avenue Asset Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2023, closing a stake of 20 shares — an estimated $7.17K sold.

Baker Avenue Asset Management first reported a position in BIO in Q2 2023 and held it in 2 quarters. The position peaked at $7.17K in Q3 2023. 483 funds tracked by Wall St. Rank hold BIO as of Q4 2023.

  • Baker Avenue Asset Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 20 Bio-Rad Laboratories Class A shares in Q4 2023, an estimated $7.17K.
  • Baker Avenue Asset Management first reported a position in Bio-Rad Laboratories Class A in Q2 2023 and held it in 2 quarters.
  • Baker Avenue Asset Management's Bio-Rad Laboratories Class A position peaked at $7.17K in Q3 2023.
  • 483 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2023.

Based on Baker Avenue Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.